Key statistics
As of last trade Denali Therapeutics Inc (DNLI:NSQ) traded at 21.04, -11.49% below its 52-week high of 23.77, set on Feb 03, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 21.14 |
|---|---|
| High | 21.48 |
| Low | 20.58 |
| Bid | 21.00 |
| Offer | 21.08 |
| Previous close | 21.18 |
| Average volume | 1.58m |
|---|---|
| Shares outstanding | 158.59m |
| Free float | 140.28m |
| P/E (TTM) | -- |
| Market cap | 3.36bn USD |
| EPS (TTM) | -2.97 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 16:11 GMT.
More ▼
- Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
- Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
- Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
- Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
- Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
- The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
- Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
- Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
- Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
- Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
More ▼
